FDA Licenses Second Samsung BioLogics Facility
Samsung BioLogics announced on Oct. 11, 2017 the company’s Songdo Plant 2 has been licensed by FDA for monoclonal antibody drug-substance production. The company reports that it has nine approvals from FDA, the European Medicines Agency, and the Pharmaceutical and Medical Devices Agency.
The 152,000-L facility joins the Songdo Plant 1, which has a capacity of 30,000 L. A third facility, with a capacity of 180,000 L, is scheduled for completion in the fourth quarter of 2018.
The company reports that it increased productivity and efficiency for Plant 2 compared to Plant 1; the facility was engineered for 10 culture mediums and one refining line; the first plant has six culture mediums and one refining line.
“We are eager to maintain and further improve our biopharmaceutical quality systems and manufacturing process in a GMP-certified manufacturing facility to provide high-quality products to our clients,” said TH Kim, CEO of Samsung BioLogics in a press statement. “We continue to be dedicated to exceeding the strictest of the quality standards and our customers’ expectations.”
Source: Samsung BioLogics
|
|---|
|
Current Issue
Maintaining Cell Line Integrity
The quality of the cell lines used to manufacture biopharmaceuticals are crucial for the production of high-quality, stable biopharmaceuticals.
A New Paradigm in Drug Development
The changing regulatory and manufacturing environment is ushering in a new approach to drug development.
Submitting Extractables and Leachables Data to Regulators
The type of product, the packaging materials being used, and the process and materials used to manufacture the product will determine when E&L data should be submitted to regulators, says Susan J. Schniepp, executive vice-president, Post-approval Pharmaceuticals and distinguished fellow at Regulatory Compliance Associates.
Outsourcing
FDA Approves Drug Product Manufacturing for Samsung BioLogics
Drug product approval from FDA follows previous approvals from European and Japanese authorities.
Joseph Polli Named AAPS President-Elect
Pharmaceutical scientist association announces upcoming term’s board of directors.
Biopharma Seeks Balance
Biopharma companies can balance competing demands from patients, investors, and regulators by keeping a focus on science.
Fifteen Years of Progress: Biopharmaceutical Industry Survey Results
This article highlights 15 years of changes in biopharmaceutical manufacturing.
Standards/Regulations
FDA Commissioner Gottlieb Releases Statement on Advancement of Gene Therapies
The agency is releasing six new draft guidances to provide a regulatory framework for handling gene therapies.
CGMP Violations Found at India Facility
FDA sent a warning letter to Goran Pharma Private Limited citing inadequate quality control violations.
Trump Drug Pricing Plan Outlines Rule Changes Pharma Can Live With
President Donald Trump announced his strategy for making prescription medicines more affordable and accessible in the United States.
Sponsored Links
